RNAC Insider Trading

Insider Ownership Percentage: 31.20%
Insider Buying (Last 12 Months): $366,519.60
Insider Selling (Last 12 Months): $0.00

Cartesian Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Cartesian Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cartesian Therapeutics Share Price & Price History

Current Price: $17.51
Price Change: Price Increase of +0.23 (1.33%)
As of 04/19/2024 03:38 PM ET

This chart shows the closing price history over time for RNAC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Cartesian Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/18/2024Timothy A SpringerDirectorBuy634$18.00$11,412.001,035,780View SEC Filing Icon  
3/14/2024Timothy A SpringerDirectorBuy21,612$16.20$350,114.401,017,228View SEC Filing Icon  
3/11/2024Timothy A SpringerDirectorBuy40$19.50$780.003,213View SEC Filing Icon  
3/8/2024Timothy A SpringerDirectorBuy160$19.80$3,168.003,173View SEC Filing Icon  
2/6/2024Timothy A SpringerDirectorBuy26$19.50$507.002,933View SEC Filing Icon  
1/17/2024Timothy A SpringerDirectorBuy26$20.70$538.202,907View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Cartesian Therapeutics (NASDAQ:RNAC)

86.95% of Cartesian Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Cartesian Therapeutics logo
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Read More on Cartesian Therapeutics

Today's Range

Now: $17.51
Low: $17.08
High: $17.75

50 Day Range

MA: $19.44
Low: $13.12
High: $23.61

52 Week Range

Now: $17.51
Low: $11.66
High: $42.60

Volume

31,212 shs

Average Volume

41,011 shs

Market Capitalization

$94.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Who are the company insiders with the largest holdings of Cartesian Therapeutics?

Cartesian Therapeutics' top insider shareholders include:
  1. Timothy A Springer (Director)
Learn More about top insider investors at Cartesian Therapeutics.